Dr Kenji Hashimoto joins the Company with over 15 years’ experience in oncology and immuno-oncology. Prior to joining Crescendo, Kenji led the clinical development for a checkpoint inhibitor in renal cell carcinoma at Roche with responsibility for multiple late phase clinical trials. Prior to that, he was Clinical Research Physician at Chugai Pharma Europe leading clinical development for a bispecific T cell engaging antibody programme as well as other early phase projects. Kenji was previously Chief Resident in Medical Oncology at the National Cancer Centre Hospital, Tokyo. He has a PhD in medical oncology from the University of Oxford and a medical degree from Gunma University in Japan.